Skip to main content
SpringerLink
Log in

In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) againstAspergillus andCandida species

  • New Antimicrobial Agents
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The in vitro activity of cilofungin (LY121019), a new semi-synthetic antifungal agent was evaluated. Potent activity was seen againstCandida albicans andCandida tropicalis, with almost identical MIC and MFC results, whereas no activity was seen against any isolates ofCandida parapsilosis or threeAspergillus spp. However, MICs were dependent on medium and test conditions chosen. It is concluded that cilofungin has good activity against some medically important yeasts in vitro, and that its in vitro activity depends on the method used.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Horn R, Wong B, Kiehn TE, Armstrong D Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Reviews of Infectious Diseases 1985, 7: 646–655.

    PubMed  Google Scholar 

  2. Meyer RD, Young LS, Armstrong D, Yu B Aspergillus complicating neoplastic disease. American Journal of Medicine 1973, 54: 6–15.

    PubMed  Google Scholar 

  3. Fainstein VF, Bodey GP, Maksymuik A, Keating M, McCredie K Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrobial Agents and Chemotherapy 1987, 31: 11–15.

    PubMed  Google Scholar 

  4. Baguley BC, Rommele G, Gruner J, Wehrli W Papulocandin B: an inhibitor of glucan synthesis in yeast spheroplasts. European Journal of Biochemistry 1979, 97: 345–351.

    PubMed  Google Scholar 

  5. Pfaller M, Riley J, Koerner T Effects of cilofungin (LY121019) on carbohydrate and sterol composition ofCandida albicans. European Journal of Clinical Microbiology and Infectious Diseases 1989, 8: 1067–1070.

    Google Scholar 

  6. Shadomy S, Espinel-Ingroff A, Cartwright RY Laboratory studies with antifungal agents: susceptibility tests and bioassays. In: Lennette EH, Balows A, Hausler WJ, Shadomy HJ (ed): Manual of clinical microbiology. American Society for Microbiology, Washington, DC, 1985, p. 991–999.

    Google Scholar 

  7. Schoenknecht FD, Sabath LD, Thornsberry C Susceptibility tests: special tests. In: Lennette EH, Balows A, Hausler WJ, Shadomy HJ (ed): Manual of clinical microbiology. American Society for Microbiology, Washington, DC, 1985, p. 1000–1008.

    Google Scholar 

  8. Kobayashi GS, Spitzer ED Testing of organisms for susceptibility to triazoles: Is it justified? European Journal of Clinical Microbiology and Infectious Diseases 1989, 8: 387–389.

    Google Scholar 

  9. Galgiani JN Antifungal susceptibility tests. Antimicrobial Agents and Chemotherapy 1987, 31: 1867–1870.

    PubMed  Google Scholar 

  10. Galgiani JN, Reiser J, Braas C, Espinel-Ingroff A, Gordon MA, Kerkering TM Comparison of relative susceptibilities ofCandida species to three antifungal agents as determined by unstandardized methods. Antimicrobial Agents and Chemotherapy 1987, 31: 1343–1347.

    PubMed  Google Scholar 

  11. Gordee RS, Zeckner DJ, Ellis LF, Thakkar AL, Howard LC In vitro and in vivo anti-candida activity and toxicology of LY121019. Journal of Antibiotics 1984, 37: 1054–1065.

    PubMed  Google Scholar 

  12. Spitzer ED, Travis SJ, Kobayashi GS Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates ofCandida species. European Journal of Clinical Microbiology and Infectious Diseases 1988, 7: 80–81.

    Google Scholar 

  13. Padula A, Chambers HF Evaluation of cilofungin (LY121019) for treatment of experimentalCandida albicans endocarditis in rabbits. Antimicrobial Agents and Chemotherapy 1989, 33: 1822–1823.

    PubMed  Google Scholar 

  14. Perfect JR, Hobbs MM, Wright KA, Durack TD Treatment of experimental disseminated candidiasis with cilofungin. Antimicrobial Agents and Chemotherapy 1989, 33: 1811–1812.

    PubMed  Google Scholar 

  15. Morrison CJ, Stevens DA Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis. Antimicrobial Agents and Chemotherapy 1990, 34: 746–750.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Disease Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York, USA

    A. Huang, F. Edwards, E. M. Bernard, D. Armstrong & H. J. Schmitt

  2. Children's Hospital, Johannes Gutenberg University, Langenbeckstraße 1, 6500, Mainz, FRG

    H. J. Schmitt

Authors
  1. A. Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. M. Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Armstrong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. J. Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, A., Edwards, F., Bernard, E.M. et al. In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) againstAspergillus andCandida species. Eur. J. Clin. Microbiol. Infect. Dis. 9, 697–699 (1990). https://doi.org/10.1007/BF01964276

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01964276

Keywords

Search

Navigation